Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

KALV – KalVista Pharmaceuticals Inc

Float Short %

53.34

Margin Of Safety %

Put/Call OI Ratio

1.85

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

15.8

Target Price

34

Analyst Recom

1

Performance Q

10.93

Upside

-984.4%

Beta

-0.35

Ticker: KALV




19 items of 1

DateSymbolLatestP/C OIP/C VolTotal OI
2026-01-23KALV16.014.2516.7810005
2026-01-26KALV14.94.3116.7510165
2026-01-27KALV14.94.331.6010235
2026-01-28KALV15.144.320.0010241
2026-01-29KALV15.654.310.0010246
2026-01-30KALV15.624.300.4010249
2026-02-02KALV16.074.301.5710254
2026-02-03KALV16.144.29999.9910269
2026-02-04KALV14.984.2715.4010220
2026-02-05KALV14.414.31999.9910298
2026-02-06KALV14.884.330.0110345
2026-02-09KALV14.791.426.0014402
2026-02-10KALV151.420.0014415
2026-02-11KALV15.541.42999.9914415
2026-02-12KALV15.121.420.0014417
2026-02-13KALV14.921.22999.9915402
2026-02-17KALV14.981.220.8015401
2026-02-18KALV15.431.220.0015403
2026-02-20KALV15.791.8520.1720761
DateSymbolLatestP/C OIP/C VolTotal OI
19 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2026-01-23KALV16.01- - -
2026-01-26KALV14.91- - -
2026-01-27KALV14.94- - -
2026-01-28KALV15.14- - -
2026-01-29KALV15.65- - -
2026-01-30KALV15.62- - -
2026-02-02KALV16.13- - -
2026-02-03KALV16.13- - -
2026-02-04KALV14.99- - -
2026-02-05KALV14.40- - -
2026-02-06KALV14.88- - -
2026-02-09KALV14.80- - -
2026-02-10KALV15.00- - -
2026-02-11KALV15.52- - -
2026-02-12KALV15.10- - -
2026-02-13KALV14.90- - -
2026-02-17KALV14.98- - -
2026-02-18KALV15.42- - -
2026-02-19KALV15.89- - -
2026-02-20KALV15.80- - -
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




19 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2026-01-23KALV-0.711.4044.70
2026-01-26KALV-0.711.3744.70
2026-01-27KALV-0.711.3744.70
2026-01-28KALV-0.711.3752.40
2026-01-29KALV-0.711.3752.40
2026-01-30KALV-0.711.3752.40
2026-02-02KALV-0.711.3452.40
2026-02-03KALV-0.711.3452.40
2026-02-04KALV-0.711.3452.40
2026-02-05KALV-0.711.3452.40
2026-02-06KALV-0.711.3452.40
2026-02-10KALV-0.710.6552.40
2026-02-11KALV-0.710.6553.02
2026-02-12KALV-0.710.6553.02
2026-02-13KALV-0.740.6553.02
2026-02-17KALV-0.721.9653.34
2026-02-18KALV-0.721.9653.34
2026-02-19KALV-0.721.9653.34
2026-02-20KALV-0.671.9653.34
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
19 items Current Page1 of 1

Last Quarter Act. EPS

Avg. EPS Est. Current Quarter

-0.78

Avg. EPS Est. Next Quarter

-0.48

Insider Transactions

-0.67

Institutional Transactions

1.96

Beta

-0.35

Average Sales Estimate Current Quarter

20

Average Sales Estimate Next Quarter

37

Fair Value

Quality Score

19

Growth Score

25

Sentiment Score

97

Actual DrawDown %

60.2

Max Drawdown 5-Year %

-89.3

Target Price

34

P/E

Forward P/E

17.4

PEG

P/S

559.54

P/B

47.07

P/Free Cash Flow

EPS

-4

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

-2.79

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-14242.57

Relative Volume

0.3

Return on Equity vs Sector %

-526.9

Return on Equity vs Industry %

-509.4

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

KalVista Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 270
KalVista Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is EKTERLY, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. KalVista Pharmaceuticals, Inc. is headquartered in Framingham, Massachusetts.
stock quote shares KALV – KalVista Pharmaceuticals Inc Stock Price stock today
news today KALV – KalVista Pharmaceuticals Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch KALV – KalVista Pharmaceuticals Inc yahoo finance google finance
stock history KALV – KalVista Pharmaceuticals Inc invest stock market
stock prices KALV premarket after hours
ticker KALV fair value insiders trading